Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of Ambrisentan in Pediatric PAH
NCT01342952Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2011
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by GSK. Started Jun 2011; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01342952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01342952.